S100A7 promotes aggressive features in breast cancer, although regulation of its expression is poorly understood. As S100A7 associates with inflammation in skin and breast tissue, we hypothesized that inflammatory cytokines may regulate S100A7 in breast cancer. We therefore examined the effects of several cytokines, among which oncostatin-M (OSM) and the related cytokine, interleukin (IL)-6, showed the most significant effects on S100A7 expression in breast tumor cells in vitro. Both cytokines consistently induced S100A7 expression in three cell lines (MCF7, T47D and MDA-MB-468) in a dose-and time-dependent manner. Induction of S100A7 was inhibited by blockade of STAT3, phosphatidylinositol 3 kinase (PI3K) and ERK1/2 signaling and small interference RNA (siRNA)-mediated knockdown of S100A7 eliminated the promigratory effects of OSM treatment. S100A7 mRNA levels in a case-control cohort of breast tumors (n ¼ 20) were significantly associated with expression of the OSM receptor b (OSMRb) chain (P ¼ 0.0098). This association was confirmed using publicly available microarray data from an independent breast tumor cohort (n ¼ 201, P ¼ 0.0005) and a correlation between S100A7 and poor patient survival was observed specifically in cases with high OSMRb expression (HR ¼ 2.35; P ¼ 0.0396; n ¼ 85). We conclude that inflammatory cytokines can regulate S100A7 expression and that S100A7 may mediate some of their effects in breast cancer.
Introduction
A growing body of evidence reveals that the host immune system can paradoxically promote or suppress tumor development depending on the disease context and immune players involved. Although adaptive, cellmediated immune responses can induce tumor regression, many tumors harbor chronically activated infiltrates of innate immune cells and dysfunctional lymphocytes that can support tumor progression (Balkwill et al., 2005; de Visser et al., 2006; Zitvogel et al., 2006) . Tumors may use numerous mechanisms to exploit immune activity, including adaptation and responsiveness to immune-derived cytokines. Interleukin (IL)-6, for example, a prominent inflammatory cytokine, was recently shown to promote spheroid formation by breast tumor progenitor cells via Notch signaling (Sansone et al., 2007) .
Along with others, we have identified S100A7 (psoriasin) as an inflammation-associated protein relevant to breast tumor progression (Emberley et al., 2004a, b; Krop et al., 2005) . S100A7 is over-expressed in ductal breast carcinomas, in which it associates with aggressive, high grade, estrogen receptor alpha (ER)-negative tumors, prominent leukocyte infiltration and poor patient outcome (Al-Haddad et al., 1999; Emberley et al., 2003a, b; 2004a, b) , consistent with its stimulatory effects on pro-survival and invasive pathways in breast cells, including PI3K, nuclear factor-kB (NFkB) and AP-1 (Emberley et al., 2005) . Although S100A7 can have both pro-and anti-tumorigenic effects in vitro, it consistently promotes tumorigenesis in vivo based on two breast xenograft mouse models, in which its expression is either upregulated in MDA-MB-231 cells or reduced in MDA-MB-468 cells (Emberley et al., 2003a, b; Krop et al., 2005; Paruchuri et al., 2008) . Although current evidence supports a role for S100A7 in promoting breast cancer, the dominant mechanisms remain to be elucidated. Furthermore, the discordance between in vitro and in vivo assays suggests that more careful consideration of the effects of the extracellular environment on S100A7 regulation and function may be required. S100A7 expression can be induced in vitro by several nonspecific stresses such as serum deprivation and high cell density, suggesting that it may be a stress response gene (Enerba¨ck et al., 2002) . In addition, S100A7 is cooperatively repressed by c-myc and BRCA1 (Kennedy et al., 2005) and is positively regulated by ERb (Skliris et al., 2007) . Nevertheless, there is a lack of information regarding well-defined environmental cues that transduce S100A7-regulatory signals.
Several groups have identified S100A7 as an epidermal response gene to inflammatory cytokines, including oncostatin M (OSM) (Gazel et al., 2006; Liang et al., 2006) . OSM is part of the IL-6 cytokine family, members of which signal through a ubiquitously expressed common receptor chain, gp130, in complex with either the OSM receptor (OSMR)b or IL-6Ra chain. By virtue of the shared activation of gp130, both OSM and IL-6 induce similar signaling cascades, involving STATs, mitogen-activated protein kinases and the phosphatidylinositol 3 kinase (PI3K) pathway (Heinrich et al., 2003) .
OSM and IL-6 regulate pleiotropic functions during inflammation. For example, IL-6, along with tumor necrosis factor (TNF)-a and IL-1b, contributes to the classically activated pro-inflammatory macrophage phenotype (Mosser and Edwards, 2008) and OSM may promote neutrophil recruitment to inflamed tissues (Modur et al., 1997) . Both cytokines are also implicated in breast cancer progression (Jorcyk et al., 2006; Grivennikov and Karin, 2008) . Several cell types may be responsible for producing these cytokines in tumors. However, while IL-6 is often expressed at high levels by malignant cells (Royuela et al., 2004) , in addition to fibroblasts and inflammatory cells, lymphocytes and macrophages may be the principal source of OSM in vivo (Liu et al., 1998) . As S100A7 associates with inflammation and promotes aggressive features in breast tumors, we set out to examine the possibility that inflammation may regulate and exert pro-tumorigenic effects through S100A7.
Results

Inflammatory cytokines induce S100A7 expression in breast cells
To determine if inflammatory cytokines can regulate S100A7 expression, we treated MCF7 cells for 24 h with 100 ng/ml of IL-6, TNF-a and IL-1b, as well as OSM and IL-22, two inflammatory cytokines known to regulate S100A7 in the epidermis (Boniface et al., 2005; Gazel et al., 2006) . We observed a robust induction of S100A7 protein after OSM treatment, and a more modest increase in response to IL-6, TNF-a and IL-1b (Figure 1 ). In spite of its role in regulating S100A7 in skin, IL-22 had no apparent effect, nor did TGF-b, generally classified as an immunosuppressive cytokine (Zou, 2005) . Synergistic effects on induction of S100A7 were observed when cells were costimulated with combinations of OSM or IL-6 and TNF-a or IL-1b (Figure 1 ). Our subsequent experiments focused on OSM and IL-6, as OSM was the strongest single inducer of S100A7 and IL-6 is in the same cytokine family.
We found S100A7 to be dose-dependently induced by OSM in MCF7 cells, with a minimum effective concentration of 10-15 ng/ml and a maximally effective concentration of 100 ng/ml (Figure 2a ). This effect was also time-dependent at both the protein and mRNA levels (Figures 2b and c) . S100A7 mRNA and protein were upregulated by 6 and 24 h post-stimulation, respectively, and peaked at 48-96 h. As expected, stimulation with IL-6 caused a weaker induction of S100A7 at late time-points when compared with OSM ( Figure 2d ). Induction of S100A7 cytosolic protein by OSM was confirmed by immunofluorescence microscopy (data not shown).
We next assessed OSM and IL-6 effects on the following cell lines: T47D, MDA-MB-231, MDA-MB-468 and ZR75. Stimulation of MDA-MB-231 or ZR75 cells with either cytokine did not affect S100A7 (data not shown). However, both T47D and MDA-MB-468 cells responded to cytokines by upregulating S100A7 expression (Supplementary Figure S1) . MDA-MB-468 cells, which possess high endogenous S100A7 expression, showed only a modest response to cytokine treatment. In contrast, T47D cells (S100A7 negative under normal growth conditions) responded by robustly inducing S100A7 on stimulation with either cytokine.
Chronic OSM exposure induces long term, stimulus-independent S100A7 expression Inflammatory cells are a highly variable component of the in vivo tumor environment and the concentrations of their cytokine products may fluctuate over time (Balkwill et al., 2005; de Visser et al., 2006; Zitvogel et al., 2006) . To determine if short-term stimulation with Figure 1 Inflammatory cytokines induce S100A7 in MCF7 cells. Cells were treated with the indicated cytokines (all at 100 ng/ml) singly or in pairs, for 24 h before being harvested for western blot analysis. Actin-normalized S100A7 band densities (relative to the OSM-treated sample) were calculated using ImageJ. Data are representative of three experiments.
OSM or IL-6 is sufficient to induce S100A7, we stimulated MCF7 cells for 2 h, after which the cells were washed and cultured in cytokine-free media. In contrast to multi-day treatment, short-term stimulation with OSM was insufficient for full induction of S100A7 expression (Figure 3a) , as was short-term IL-6 treatment (Supplementary Figure S2a) .
We next examined the long-term persistence of cytokine-induced S100A7 expression. MCF7 cells treated with OSM for 96 h, followed by cytokine removal, showed an approximately 50% reduction in S100A7 mRNA after 72 h in cytokine-free media but maintained high S100A7 protein levels (Figures 3b and c) . Similar results were obtained using IL-6 (Supplementary Figure  S2b) . Although levels of activated STAT3, Akt and ERK1/2 diminished as expected immediately after OSM removal (Figure 3b ), these levels recovered soon after, despite the lack of exogenous stimulation. This suggests that long-term stimulation with OSM triggers a mechanism maintaining activation of signaling pathways that may promote persistent S100A7 expression.
OSM induces S100A7 through multiple signaling pathways OSM or IL-6 stimulation of breast cells triggers several signaling pathways, including those of STAT3, PI3K and ERK1/2 (Heinrich et al., 2003) . OSM additionally activates the stress-activated mitogen-activated protein kinases p38 and JNK (Heinrich et al., 2003) . As shown in Figure 2b , STAT3, PI3K and ERK1/2 were effectively engaged over an extended time course by OSM stimulation in our cells.
To identify the pathways necessary for S100A7 expression, we selectively inhibited each of the above kinases during cytokine treatment. Inhibition of either PI3K (using LY294002) or ERK1/2 (using U0126) completely abrogated S100A7 induction by OSM and IL-6 (Figure 4a ). Conversely, inhibition of JNK or p38 had no effect (Supplementary Figure S3) . Blockade of STAT3 signaling by means of STAT3-specific small interference RNA (siRNA) or over-expression of a dominant-negative STAT3 mutant (Y705F) also inhibited full induction of S100A7 expression (Figures 4b and c). Thus, activation of PI3K, ERK1/2 and STAT3 all appear to be necessary for full S100A7 induction by OSM or IL-6. We (Emberley et al., 2005; Wang et al., 2008) and others (Paruchuri et al., 2008) have previously shown a link between S100A7 and the epidermal growth factor (EGF) pathway. IL-6 and EGF signaling can also be functionally linked (Badache and Hynes, 2001) . To begin to explore this connection, we inhibited epidermal growth factor receptor (EGFR) using AG1478 and observed a marked inhibition of S100A7 expression after OSM treatment, accompanied by loss of Akt activation (Supplementary Figure S4) . Furthermore, EGF mRNA levels increased during OSM treatment and remained elevated after cytokine removal. Thus, OSM and IL-6 induce S100A7 in MCF7 cells through a complex mechanism involving PI3K, ERK1/2, STAT3, and potentially autocrine EGF signaling. S100A7 mediates IL-6 and OSM-dependent migration A hallmark of OSM-stimulated MCF7 or T47D cells is increased migration and invasiveness, accompanied by altered morphology (Zhang et al., 2003; Holzer et al., 2004; Jorcyk et al., 2006) . To determine if S100A7 is involved in these previously characterized phenotypic changes, we used siRNA to inhibit S100A7 expression during cytokine stimulation in MCF7 cells and assessed cell morphology and migratory capacity. Although control transfection with green fluorescent proteinspecific siRNA had little effect on OSM-induced morphology change, it was largely prevented by knockdown of S100A7 (Figure 5a) . Similarly, siRNA knockdown of S100A7 also abrogated the marked promigratory effect of OSM and IL-6 on this cell line, as measured in the under-agar migration assay (Figure 5b , Supplementary Figure S5) , showing functional relevance of S100A7 in the context of cytokine stimulation. Knockdown of S100A7 by siRNA was verified by western blot (Figure 5c ). S100A7 is associated with the OSM/IL-6 pathway in vivo To determine if S100A7 associates with OSM-related genes in vivo, we assessed mRNA expression in a cohort of 20 breast tumors. Using semi-quantitative reverse transcriptase-PCR (RT-PCR), we examined the mRNA levels of OSM, OSMRb, IL-6, IL-6Ra, gp130 and LIF (an additional IL-6 family cytokine), normalized to GAPDH (Figure 6a ). S100A7 mRNA expression was first reassessed to confirm previously determined S100A7 status based on immunohistochemistry (IHC).
We observed 90% concordance between IHC and RT-PCR detection of S100A7, but with two samples previously classified as S100A7 negative by IHC showing weak S100A7 mRNA expression by RT-PCR. These samples were reclassified as S100A7 positive for comparison with mRNA levels of cytokine pathway genes. Only expression of OSMRb was significantly higher (P ¼ 0.0098) in S100A7-positive tumors (Figure 6b ). However, in secondary analysis, in which S100A7-positive status was reassigned to the subgroup of tumors with higher levels of S100A7 mRNA and IHC expression (cases 1-8) versus those with absent or low expression, OSM (P ¼ 0.041), IL-6Ra (P ¼ 0.049) and OSMRb (P ¼ 0.023) were significantly associated with S100A7-high cases. No significant trends were evident for IL-6, LIF or gp130.
To confirm these observations in a larger independent cohort, we obtained publicly available microarray gene expression data from 201 breast tumors in a previously published data set (Herschkowitz et al., 2007) , accessed through the University of North Carolina (UNC) microarray database. Spearman correlation of Log2 normalized expression ratios revealed a strong association between S100A7 and OSMRb (P ¼ 0.0005) that was retained in the ER-negative subset (P ¼ 0.0013). Additional correlation data are provided in Supplementary Table S2 . If S100A7 mediates aggressive features downstream of cytokine stimulation, this may be reflected in clinical patient outcome. Using the UNC data set, we sorted interpretable tumors into those with greater (n ¼ 85) or less than (n ¼ 78) the median OSMRb expression level and compared overall survival of patients with high (Log2 ratio >1) and low (Log2 ratio o1) S100A7 expression within each group (Supplementary Figure  S6) . S100A7 correlated significantly with reduced patient survival within the OSMRb-high population (HR ¼ 2.35, 95% confidence interval 1.04-5.31; P ¼ 0.0396), but not the OSMRb-low population (HR ¼ 1.04, 95% confidence interval 0.29-3.74; P ¼ 0.9489). Collectively, these data support the notion that OSM and S100A7 are functionally related in breast cancer, and suggest that S100A7 is a poor prognostic factor primarily in the context of tumor inflammation and cytokine signaling. Discussion S100A7 is commonly upregulated in breast cancer, most frequently in ductal carcinoma in situ with a high grade, ER-negative phenotype (Emberley et al., 2004a, b) . The frequent association of inflammation with this tumor phenotype supports the view that S100A7 may be a chemotactic factor for inflammatory cells (Jinquan et al., 1996; Wolf et al., 2008 ), although it is also possible that inflammation may precede and stimulate S100A7. We have shown here that two IL-6 family cytokines, OSM and IL-6, regulate S100A7 in breast cell lines via (in MCF7 cells) PI3K, ERK1/2 and STAT3 signaling. Furthermore, we have shown that S100A7 can mediate the effects of OSM on cell morphology and migration. In addition, we have confirmed that a relationship between the OSM pathway and S100A7 exists in breast tumors in vivo that has relevance to prognosis. It is noteworthy that although we identified four cytokines capable of inducing S100A7 expression in vitro (OSM, IL-6, TNF-a and IL-1b; Figure 1 ), only the OSM pathway correlates with S100A7 levels in vivo (Figure 6 ; Supplementary Table S2) .
OSM and IL-6 are produced during inflammatory responses by activated T lymphocytes and macrophages (Naka et al., 2002; Tanaka and Miyajima, 2003) . Both IL-6 and OSM exert a variety of effects on breast cancer cells and those of other tumor types. Numerous investigators have examined the role of IL-6 in breast cancer and have shown it to exert both pro-and antitumor effects in a context-dependent manner (Knu¨pfer and Prei, 2007) . The role of OSM in cancer has been less well studied. As OSM is cytostatic to breast tumor cells in vitro, it was initially thought to have potential therapeutic value. Subsequent studies, however, have revealed that this potential may be limited by the ability of OSM to enhance migration and invasiveness (Zhang et al., 2003; Holzer et al., 2004; Jorcyk et al., 2006) . The effects of OSM and IL-6 may contribute to the common observation that chronic inflammation can promote tumorigenesis (Balkwill et al., 2005; de Visser et al., 2006; Zitvogel et al., 2006) . Indeed, we have shown here that OSM may mediate aggressive features via S100A7 expression, and that the OSM/S100A7 axis correlates with reduced patient survival.
Although S100A7 can be highly expressed in breast tumors and is implicated as a gene induced by several forms of cell stress (Di Nuzzo et al., 2000; Enerba¨ck et al., 2002) , specific mechanisms regulating S100A7 in breast cells have remained elusive. Nevertheless, in nonneoplastic skin pathologies, several investigators have reported S100A7 induction in response to inflammatory cytokines, including OSM, IL-1, IL-17, IL-20 and IL-22 (Boniface et al., 2005; Gazel et al, 2006; Liang et al., 2006; Wolk et al., 2006; Bando et al., 2007; Boniface et al., 2007; Sa et al., 2007) . Each of these cytokines has the capacity to signal, either directly or indirectly, through STAT3, ERK1/2 and PI3K (Heinrich et al., 2003; Pestka et al., 2004; Gaffen, 2008; Perrier et al., 2008) . We have shown previously that S100A7 in breast tumors correlates with Akt activation (Emberley et al., 2005) and now show that OSM and IL-6 can induce S100A7 via PI3K, ERK1/2 or STAT3. We speculate that this may reflect convergence of all three pathways on the same regulator of S100A7. One possible candidate may be a member of the C/CAAT enhancer binding protein (C/EBP) transcription factors. C/EBPb and C/EBPd are both expressed downstream of IL-6 (Conze et al., 2001) . Furthermore, the S100A7 promoter contains multiple C/EBPb recognition sites and S100A7 correlates strongly with C/EBPb in the UNC microarray data set (Supplementary Table S2 ). In sum, current data suggest that OSM/IL-6 can induce S100A7 through a complex multi-tiered signaling network, a clearer understanding of which will be an important goal for future study.
In support of the premise that chronic inflammation exacerbates tumor progression, we found that shortterm cytokine stimulation of MCF7 cells was insufficient to induce S100A7, suggesting that sustained inflammatory conditions may be required. Although STAT3, ERK1/2 and PI3K mediate S100A7 expression, they may not do so directly, as their activation precedes S100A7 mRNA induction by several hours. As a direct target of these pathways should become rapidly activated, this implies that an additional event(s) takes place. This may be related to signals emanating from changes in adhesion or the cytoskeleton, but further exploration of this possibility will be confounded by the observation that S100A7 itself can mediate these changes.
Alternatively, the delay in S100A7 expression may reflect the time required to achieve a critical threshold of signal strength. Indeed, the levels of activated STAT3, ERK1/2 and Akt increase steadily during the first 24 h of OSM treatment, perhaps as a result of positive feedback (Daur et al., 2005) . Furthermore, as a target gene of NFkB, IL-6 expression can be triggered by Akt and maintained by subsequent autocrine stimulation (Yang et al., 2007) .
Our data also suggest that high-level induction of S100A7 by OSM may require EGF autocrine signaling. Although our data are preliminary this is intriguing, given previous observations that S100A7 itself may promote EGF expression and is involved in EGFR signaling (Emberley et al., 2005; Paruchuri et al., 2008; Wang et al., 2008) . We have confirmed by analysis of expression levels in an independent breast tumor data set (UNC) that S100A7 correlates with EGFR expression in a large unselected cohort and within the ER-negative subset, supporting the existence of functional cooperativity between S100A7 and EGFR (Supplementary Table S2) .
Once induced by OSM, S100A7 levels appear to remain elevated after cytokine withdrawal. This suggests that, once expressed at high levels in vivo, S100A7 expression may persist despite downstream fluctuations in cytokine concentration. From a practical standpoint, this phenomenon would complicate research efforts directed at correlating S100A7 with specific inflammatory mediators in vivo. Stability of the S100A7 mRNA and protein are unknown but may be a factor in this persistence. The closely related S100A8 gene shows an mRNA half life of B8 h that can be increased up to 20 h by glucocorticoid treatment (Hsu et al., 2005) . Similarly, S100A4 mRNA and protein half life has been shown to be B8 h and B85 h, respectively (Rivard et al., 2007) . However, several other possible mechanisms may underlie this observation. First, autocrine production of IL-6 may continuously drive signals that sustain S100A7 expression. Second, S100A7 itself may establish an autocrine loop, as it is secreted and a putative ligand for the receptor for advanced glycation end-products, a promiscuous receptor that signals through NFkB and mitogen-activated protein kinases (Enerba¨ck et al., 2002; Wolf et al., 2008) . Autocrine EGF signaling constitutes another potential mechanism, but is not supported by preliminary evidence (data not shown). Another explanation is based on the role of S100A7 in OSM-induced migration. In MCF7 and T47D cells, fibronectin is upregulated by OSM (Zhang et al., 2003) and, in multiple myeloma, can activate STAT3 in cooperation with IL-6 via b1 integrin signaling (Shain et al., 2009) . If S100A7 mediates OSM-induced migration in MCF7 cells, it may also regulate STAT3 through integrin signaling. In turn, sustained STAT3 activity could maintain S100A7, perpetuating a loop of pro-migratory signals. The potential S100A7-regulatory mechanisms described above are summarized in Supplementary Figure S8 . S100A7 is strongly associated with ER-negative status in breast cancer. On the basis of our studies of invasive breast cancer, S100A7 is expressed in approximately 50% of ER-negative versus 20% of ER-positive tumors (Al-Haddad et al., 1999; Emberley et al., 2003a Emberley et al., , b, 2004a . Similar ratios were observed in ductal carcinoma in situ, in which 80% of ER-negative and 30% of ER-positive pure ductal carcinoma in situ lesions were S100A7 positive (Emberley et al., 2004a, b) . We currently show that OSM/IL-6 can induce S100A7 in ER-positive MCF7 and T47D cells, although the OSM/IL-6 pathway is associated in vivo with S100A7-positive tumors that are predominantly ER negative. The reason for the association of S100A7 with ER-negative status in vivo is unknown. However, it may be relevant that OSM was shown to dramatically reduce ER expression in MCF7 cells (Grant et al., 2002) , an observation that we have verified (Supplementary Figure S7) . Furthermore, IL-6 correlates with ERnegative status and poor prognosis in breast cancer patients (Knu¨pfer and Prei, 2007) . Therefore, it is possible that OSM/IL-6 signaling may downregulate ER and drive ER-positive breast tumors toward an ERnegative phenotype while concurrently upregulating S100A7, providing a rationale for the link between S100A7 and ER-negative tumor status.
It was recently reported that treatment of breast cells with interferon-g, a signature cytokine of cell-mediated (Th1) immune responses, suppressed endogenous S100A7 expression (Petersson et al., 2007) . OSM and IL-6 differ from interferon-g in that they function more generally as pleiotropic inflammatory signals. Thus, while inflammatory cytokines may positively regulate S100A7, Th1 cytokines could have an opposing effect. This notion is supported by our analysis of microarray data, which reveals a positive correlation between S100A7 and OSMRb within ER-negative tumors, in contrast to a negative correlation with interferon-g (Supplementary Table S2 ).
Although effective anti-tumor adaptive immune responses can be associated with improved clinical outcome, festering intratumoral inflammation is thought to promote malignancy. Indeed, the ability of tumor cells to exploit immune responses for their own benefit by diverse means is increasingly documented (Balkwill et al., 2005; de Visser et al., 2006; Zitvogel et al., 2006) . Expression of S100A7 may represent a novel strategy for malignant cells to translate potentially damaging immune responses into beneficial stimuli. It will be important to achieve a broader understanding of the specific immune parameters regulating S100A7 in the breast, which may reveal additional strategies for targeting S100A7 therapeutically. Furthermore, such knowledge could be relevant in the development of cancer immunotherapies, for which S100A7 expression may be a confounding and potentially damaging side effect of treatment.
In conclusion, S100A7 is influenced by the inflammatory cytokines OSM and IL-6 in breast cancer and may regulate their pro-invasive effects. Together with previous data implicating S100A7 in tumor cell survival, these data further support a role for S100A7 in tumor progression. Given the prominence of S100A7 expression in preinvasive ductal carcinoma in situ, this also supports the concept that inflammation can influence the earliest stages of breast cancer development through specific modulation of breast cancer gene expression. Further investigation of specific inflammatory conditions regulating S100A7 in breast cancer is warranted, and may reveal novel strategies to target S100A7 therapeutically.
Materials and methods
Cell culture, transfection and cytokine stimulation Human breast carcinoma cell lines MCF7, T47D, ZR75, MDA-MB-231 and MDA-MB-468 (obtained originally from ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium with 5% fetal bovine serum under standard conditions. Characteristic features of cultured lines (morphology, doubling time, and so on) are continually monitored for detection of potential cross-contamination by light microscopy. For stimulation assays, viable cells were seeded into 12-well plates (Corning, Lowell, MA, USA) at 100 000 cells per well (40 000 for long-term withdrawal assays). Human OSM, IL-6, TNF-a, IL-1b, IL-22 and TGF-b (Peprotech, Rocky Hill, NJ, USA) were stored as 10 mg/ml stocks in culture media. For withdrawal assays, cytokinespiked media was aspirated, cells were washed twice with sterile phosphate-buffered saline, and further cultured in cytokine-free media. Inhibitors to MEKK1/2 (U0126; Cell Signaling, Danvers, MA, USA), PI3K (LY294002), p38 mitogen-activated protein kinase (SB203580), EGFR (AG1478) or JNK (JNK inhibitor VIII; Calbiochem, San Diego, CA, USA) were added (all 10 mM) to cultures 30 min before cytokine stimulation. Transient transfection of dominant negative, flag-tagged STAT3 (Y705F; in pRc/CMV; Addgene plasmid 8709 (Wen and Darnell, 1997) ) or empty vector DNA was performed using Lipofectamine (Invitrogen, Burlington, ON, Canada) 2 days before cytokine stimulation. Transfection of STAT3 or S100A7-specific ON-TARGET plus siRNA (Dharmacon, Lafayette, CO, USA) or green fluorescent protein-specific siRNA (Qiagen, Mississauga, ON, Canada) was conducted using Dharmafect-4 reagent (Dharmacon). Light micrographs were captured using a QICAM camera (QIMAGING, Surrey, BC, Canada) with an Axiovert 40 CFL light microscope (Zeiss, Toronto, ON, Canada).
Western blot
Cells were prepared for western blotting as described previously (Al-Haddad et al., 1999) . Protein concentrations were estimated by absorbance at 280 nm using an ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). Primary antibodies were S100A7 (1:1000; Abcam, Cambridge, MA, USA), GAPDH ( ; 1:500), ERK1/2 (1:1000) and Flag (1:500; Cell Signaling). Secondary antibodies were horseradish peroxidase-conjugated bovine anti-rabbit and goat anti-mouse IgG (1:3000; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Reverse transcriptase-PCR Breast tumor samples from primary invasive ductal carcinomas were obtained from the Manitoba Breast Tumor Bank (Winnipeg, MB, Canada), which operates with approval from the research ethics board of the Faculty of Medicine, University of Manitoba. Tissues are accrued to the bank and frozen at -70 1C. A portion of the frozen tissue from each case is processed to create matched formalin-fixed paraffinembedded and frozen tissue blocks. We constructed a casecontrol cohort by selecting ten S100A7-positive breast tumors from a larger series of tumors that had been previously assessed by IHC performed on the paraffin blocks (Emberley et al., 2003a, b) , and from which frozen tissue blocks were still available, and randomly selected 10 additional S100A7 IHCnegative tumors as controls.
Total RNA was extracted from frozen tissue and cultured cells using the Qiagen RNEasy Mini kit. One mg of RNA per sample was reverse-transcribed using MMLV reverse transcriptase as per manufacturer instructions (Invitrogen). Primer sequences and cycling conditions for PCR are provided in Supplementary Table S1 . PCR products were electrophoresed, stained with ethidium bromide and imaged using a FluorChem 5500 (Alpha Innotech, San Leandro, CA, USA). Band intensities were assessed using ImageJ (NIH, Bethesda, MD, USA). Three independent assays were performed per target, per experiment.
Under-agar migration assay Migration assays were conducted using six-well plates (Corning) containing semi-solid base-layers of Dulbecco's modified Eagle's medium, 5% serum and 0.5% sterile agar (2.5 ml per well). One-cm round plugs were removed from base layers using a bore, producing cylindrical wells within the agar and exposing plate plastic. Equal numbers of viable cells were plated into the agarwells and cultured for 24 h. Cells that migrated away from well edges (excluding those still in contact with well edges) were counted in three high-power fields (400 Â ) per well and averaged. Each experiment was performed in triplicate.
Statistical analyses
Migration assay results were analyzed using Student's t-test. Tissue mRNA levels were compared using Mann-Whitney T-test. P-values o0.05 were considered statistically significant. All operations were performed using Prism 5.0 (GraphPad, La Jolla, CA, USA).
